Clinical Trials Browser

Unknown × Carcinoma, Non-Small-Cell Lung × Pemetrexed × Clear all

NCT06277674 2024-03-08

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06110663 2023-11-01

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05810350 2023-04-13

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01656551 2023-03-24

MILES-4

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05741021 2023-02-24

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05574998 2022-10-12

FTANLCNDG

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05507606 2022-08-19

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05458726 2022-07-26

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05273814 2022-07-13

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05448781 2022-07-07

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05430802 2022-06-24

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01951469 2022-03-08

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Phase 3 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02607592 2022-02-25

NACA

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02743923 2021-12-21

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04989322 2021-12-08

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04405674 2021-11-22

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04943029 2021-09-02

NEOSUN

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04586465 2021-08-24

DYNAPET

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02448797 2021-07-20

EVIDENCE

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04768075 2021-02-24

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04706949 2021-01-13

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03402048 2020-11-04

EPIC

Phase 3 Unknown

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04592666 2020-10-19

APPEAL

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04500704 2020-08-05

ACROSS1

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04470076 2020-07-14

Neoafa

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02076477 2020-03-17

OITROLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02725918 2020-02-12

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04054531 2019-09-10

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03062800 2019-06-05

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03647956 2019-04-17

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03374280 2019-03-28

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03489616 2018-04-05

CRAGMOLC

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung

NCT03201146 2017-11-17

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02974933 2017-02-17

Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03050437 2017-02-10

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02568033 2017-01-31

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

Phase EARLY_PHASE1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03002844 2016-12-28

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02579564 2016-10-21

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung